This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Daiichi Sankyo Co., Ltd.

Drug Names(s): AC220, ASP2689

Description: AC220 targets the kinase FLT3, which is mutated and constitutively activated in 25-40 percent of Acute Myeloid Leukemia (AML) patients, causing poor prognosis and decreased response to existing treatments including chemotherapy and stem cell treatments. AC220 binds potently and specifically to FLT3 with sub-nanomolar inhibition of FLT3 phosphorylation in an AML cell line derived from human patients. In preclinical studies, AC220 has shown a superior pharmacokinetic and safety profile, with no significant inhibition of the five human CYP isoforms. AC220 is orally bioavailable and has been shown to induce tumor regression in a xenograft model at low doses.

Using its KinomeScan technology, Ambit engineered AC220 to potently target FLT3, KIT, CSF1R/FMS, RET and PDGFRa/b kinases, all of which are validated drug targets.

Deal Structure: AC220 was originally developed by Ambit Biosciences.

Ambit and Astellas
In December 2009, Ambit and Astellas Pharma entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. This partnership includes AC220. The companies will collaborate to develop AC220 for AML and other indications. The parties will also collaborate on a research and development program for a series of novel FLT3 inhibitors for a variety of oncology and non-oncology indications. The companies will share equally in the responsibilities and expenses for the development of AC220 and any additional products in the U.S. and Europe, while Astellas will have sole responsibility to fund development in all other territories. Under the terms of the agreement, Ambit will receive an up-front cash payment of $40 million and will be eligible to receive pre-commercialization payments of up to $350 million.

In March 2013, Astellas...See full deal structure in Biomedtracker

Quizartinib News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug